Health and Healthcare
Johnson & Johnson Crushes Expectations With Strong Q1
Published:
Last Updated:
Johnson & Johnson (NYSE: JNJ) released its most recent quarterly results before the markets opened on Tuesday. For the first quarter, the pharmaceutical giant said that it had $2.30 in earnings per share (EPS) and $20.69 billion in revenue, compared with consensus estimates that called for $1.99 in EPS and revenue $19.48 billion. The same period of last year reportedly had EPS of $2.10 on $20.02 billion in revenue.
Consumer Health sales increased 9.2% on an adjusted operational basis to $3.63 billion. This was driven primarily by over-the-counter products, including Tylenol and Motrin analgesics; upper respiratory products, including Zyrtec; digestive health products: and Zarbee’s Naturals.
Pharmaceutical sales increased 10.2% to $11.13 billion. This increase was driven by Stelara (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases; Darzalex (daratumumab), for the treatment of multiple myeloma; Imbruvica (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer; among other drugs.
Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, declined by 4.8%, driven by the estimated net negative impact of the COVID-19 pandemic and the associated deferral of medical procedures to its Surgery, Orthopaedics, Interventional Solutions and Vision businesses.
Looking ahead to the 2020 full year, Johnson & Johnson expects to see EPS in the range of $7.65 to $8.05 and adjusted operational sales between $79.2 billion and $82.2 billion. Consensus estimates are calling for $8.08 in EPS and $79.63 billion in revenue for the year.
Alex Gorsky, board chair and chief executive, commented:
With Johnson & Johnson’s century-plus history of leading in times of great challenge, we are mobilizing our resources across the Company in the fight against the COVID-19 pandemic. Johnson & Johnson is built for times like this, and we are leveraging our scientific expertise, operational scale and financial strength in the effort to advance the work on our lead COVID-19 vaccine candidate. We are committed to beginning production at risk imminently and bringing an affordable and accessible vaccine to the public on a not-for-profit basis for emergency pandemic use.
Separately, the board of directors declared a 6.3% increase in the quarterly dividend rate, from $0.95 per share to $1.01 per share. At the new rate, the indicated dividend on an annual basis is $4.04 per share, compared to the previous rate of $3.80 per share.
Johnson & Johnson stock traded up over 4% on Tuesday, at $146.20 in a 52-week range of $109.16 to $154.50. The consensus price target is $155.41.
Is Your Money Earning the Best Possible Rate? (Sponsor)
Let’s face it: If your money is just sitting in a checking account, you’re losing value every single day. With most checking accounts offering little to no interest, the cash you worked so hard to save is gradually being eroded by inflation.
However, by moving that money into a high-yield savings account, you can put your cash to work, growing steadily with little to no effort on your part. In just a few clicks, you can set up a high-yield savings account and start earning interest immediately.
There are plenty of reputable banks and online platforms that offer competitive rates, and many of them come with zero fees and no minimum balance requirements. Click here to see if you’re earning the best possible rate on your money!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
